In the research conducted by our team, it was found that “Primidone,” a RIPK1 inhibitor, could delay the onset of motor deficits in the ALS animal model, the SOD1 G93A transgenic mice. Here, RIPK1 is linked to amyotrophic lateral sclerosis.